Skip to main content

Barinthus Biotherapeutics plc.

corporate_fare Company Profile

Barinthus Biotherapeutics plc.

BRNS·NASDAQ·Life Sciences·CIK 0001828185

Barinthus Bio is a clinical-stage biopharmaceutical company focused on developing new immunotherapeutic drug candidates for autoimmune and inflammatory diseases. The company prioritizes its SNAP-TI platform, designed to promote immune tolerance by guiding T cells to reduce inflammation and restore natural immune non-responsiveness to healthy tissue. Its lead candidate, VTP-1000, aims to restore immune non-responsiveness to gluten in celiac disease patients and is currently in a Phase 1 clinical trial. Barinthus Bio believes the SNAP-TI platform could impact multiple other autoimmune and inflammatory conditions. The company is also exploring partnerships for VTP-300, a product candidate for chronic hepatitis B (CHB). VTP-300 uses viral vector platform technologies, Chimpanzee Adenovirus Oxford (ChAdOx) and Modified Vaccinia Ankara (MVA), to increase disease-specific CD8+ T cells. VTP-300 is a Phase 2 immunotherapeutic treatment modality intended as part of a regimen to achieve functional cure in chronically infected hepatitis B patients. The company leverages its understanding of T cell function, which are key to the body's ability to identify and respond to threats through antigen recognition.

Barinthus Biotherapeutics plc. (NASDAQ:BRNS) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 20 items for BRNS at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-09-01, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 15 rated 8 or above. Recent SEC coverage for BRNS spans 8-K, 10-Q, DEF 14A, DEFM14A.

Recent high-impact activity:

  • UK Court Sanctions Barinthus Merger; Nasdaq Halt Set for Sept 9
  • Barinthus Bio Sets 0.111 Exchange Ratio, Delisting Sept 3 as Clywedog Merger Nears Close
  • Barinthus Bio Q2 2026: $59.6M Cash, VTP-1000 Enrollment Complete, Clywedog Merger on Track
  • Barinthus Bio Reports Q2 Loss, Nasdaq Delisting Extension, and Merger Progress
  • Barinthus Biotherapeutics Receives Nasdaq Delisting Extension, Moves to Capital Market

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$0
Net Income
-$66.43M
Diluted EPS
-$1.64
Op. Cash Flow
-$47.98M
Free Cash Flow
-$48.02M
Operating Income
-$70.56M
Cash & Equivalents
$70.46M
Debt / Equity
0.00×
Shares Outstanding
40.85M sh
Source: 10-K · filed 2026-03-13 · accession 0001828185-26-000012
Browse all tickers starting with B →

No longer listed

BRNS (Barinthus Biotherapeutics plc.) is no longer listed on a major US exchange, so Wiseek no longer shows market data for this symbol. It last appeared on NASDAQ. The filings and coverage below remain available as an archive.

feed BRNS - Latest Insights

BRNS
Sep 01, 2026, 5:13 PM EDT
Filing Type: 8-K
Importance Score:
8
BRNS
Aug 25, 2026, 6:01 AM EDT
Filing Type: 8-K
Importance Score:
8
BRNS
Aug 06, 2026, 8:49 AM EDT
Filing Type: 8-K
Importance Score:
8
BRNS
Aug 06, 2026, 8:46 AM EDT
Filing Type: 10-Q
Importance Score:
8
BRNS
Jul 02, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
8
BRNS
Jun 10, 2026, 5:05 PM EDT
Filing Type: DEF 14A
Importance Score:
8
BRNS
May 21, 2026, 6:03 AM EDT
Filing Type: 8-K
Importance Score:
8
BRNS
Apr 30, 2026, 7:43 AM EDT
Filing Type: 10-Q
Importance Score:
8
BRNS
Apr 30, 2026, 7:32 AM EDT
Filing Type: 8-K
Importance Score:
8
BRNS
Apr 30, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
7
BRNS
Apr 30, 2026, 6:00 AM EDT
Filing Type: DEFM14A
Importance Score:
9
BRNS
Apr 22, 2026, 4:30 PM EDT
Filing Type: 8-K
Importance Score:
7
BRNS
Apr 13, 2026, 3:33 PM EDT
Filing Type: SCHEDULE 13D
Importance Score:
7
BRNS
Mar 31, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
7
BRNS
Mar 16, 2026, 8:47 AM EDT
Source: Reuters
Importance Score:
7
BRNS
Mar 13, 2026, 8:13 AM EDT
Filing Type: 10-K
Importance Score:
9
BRNS
Mar 13, 2026, 8:03 AM EDT
Filing Type: 8-K
Importance Score:
8
BRNS
Feb 23, 2026, 6:29 AM EST
Filing Type: 425
Importance Score:
8
BRNS
Feb 23, 2026, 6:02 AM EST
Filing Type: 8-K
Importance Score:
8
BRNS
Jan 06, 2026, 4:09 PM EST
Filing Type: 8-K
Importance Score:
9
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets